Correlation of homologous recombination deficiency induced mutational signatures with sensitivity to PARP inhibitors and cytotoxic agents

Abstract Background Homologous recombination (HR) repair deficiency arising from defects in BRCA1 or BRCA2 is associated with characteristic patterns of somatic mutations. In this genetic study, we ask whether inactivating mutations in further genes of the HR pathway or the DNA damage checkpoint also give rise to somatic mutation patterns that can be used for treatment prediction. Results Using whole genome sequencing of an isogenic knockout cell line panel, we find a universal HR deficiency-specific base substitution signature that is similar to COSMIC signature 3. In contrast, we detect different deletion phenotypes corresponding to specific HR mutants. The inactivation of BRCA2 or PALB2 leads to larger deletions, typically with microhomology, when compared to the disruption of BRCA1, RAD51 paralogs, or RAD54. Comparison with the deletion spectrum of Cas9 cut sites suggests that most spontaneously arising genomic deletions are not the consequence of double-strand breaks. Surprisingly, the inactivation of checkpoint kinases ATM and CHK2 has no mutagenic consequences. Analysis of tumor exomes with biallelic inactivating mutations in the investigated genes confirms the validity of the cell line models. We present a comprehensive analysis of sensitivity of the investigated mutants to 13 therapeutic agents for the purpose of correlating genomic mutagenic phenotypes with drug sensitivity. Conclusion Our results suggest that no single genomic mutational class shows perfect correlation with sensitivity to common treatments, but the contribution of COSMIC signature 3 to base substitutions, or a combined measure of different features, may be reasonably good at predicting platinum and PARP inhibitor sensitivity.

Abstract licence: CC BY-NC-ND

1. 2.

   Rad51 Paralogs Remodel Pre-synaptic Rad51 Filaments to Stimulate Homologous Recombination · 2015

2. 21.
   Corrected

   Mutational Processes Molding the Genomes of 21 Breast Cancers · 2012

3. 22.

   Trimmomatic: a flexible trimmer for Illumina sequence data · 2014

4. 36.

   deconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution · 2016

5. 42.

   A comprehensive survey of the mutagenic impact of common cancer cytotoxics · 2016

6. 43.
   Corrected

   Loss of BRCA1 or BRCA2 markedly increases the rate of base substitution mutagenesis and has distinct effects on genomic deletions · 2016

7. 53.

   MRE11 and EXO1 nucleases degrade reversed forks and elicit MUS81-dependent fork rescue in BRCA2-deficient cells · 2017

8. 54.

   Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes · 2017

9. 56.

   Role of BRCA Mutations in the Modulation of Response to Platinum Therapy · 2018

10. 58.

    MutationalPatterns: comprehensive genome-wide analysis of mutational processes · 2018

11. 61.

    Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes · 2018

12. 62.

    Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors · 2018

13. 64.
    Corrected

    The repertoire of mutational signatures in human cancer · 2020

51 more references, whose wording the paper’s licence keeps private.

• The genomic and transcriptional landscape of primary central nervous system lymphoma · 2022

• Pan-cancer landscape of homologous recombination deficiency · 2020

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.